VACCINATION FOR HIV AND AIDS

该计划项目是一个多学科的协调努力 旨在通过开发HIV-1疫苗预防艾滋病。 该提案包括HIV-1毒株的重要问题 与SIV的变异和交叉免疫原性， 常规和新型HIV免疫原的组合物、毒性 艾滋病毒特异性体液和细胞免疫的检测和诱导 在小动物中进行的试验，以及候选疫苗在艾滋病毒- 挑战黑猩猩。 候选疫苗的选择 在黑猩猩中的功效测试和可能的用于人类的规模扩大将， 因此，应基于系统的科学方法，包括 对体液免疫应答的定量估计， 在豚鼠和恒河猴的细胞水平。 具体 本计划项目资助提案的总体目标如下： 如下所示： 1)为了比较几种HIV-1毒株，这些毒株是根据 毒性的临床特征、生物学特性和血清分型 以及豚鼠和恒河猴的免疫原性。 2)根据目标#1中获得的结果，开发候选HIV- 1疫苗制剂使用：a）灭活的全病毒，B） 基因工程pol突变体，c）重组DNA包膜 和在酵母和哺乳动物细胞中表达的核心亚基，和d） 有效的佐剂。 3)检测最佳HIV-1疫苗材料的效力， 根据上述结果选择的方案， 保护未感染的黑猩猩免受HIV-1攻击。 该项目由5个实验室组成 （项目一至五）在4个不同的机构， 病理学，加州大学戴维斯分校，医学院 （UCD）（项目I），B）肿瘤病毒实验室，癌症研究 加州大学旧金山分校弗朗西斯科（UCSF）（项目 c）Chiron Corporation，Emeryville，CA（Project III），d） 癌症研究所脂质体实验室（项目 e）西南生物医学研究基金会，San 得克萨斯州安东尼奥（项目五）。 我们相信这个财团 通过提供科学人才，独特的资源和 行政能力，以执行必要的团队合作 以实现既定目标。

This Program Project is a multidisciplinary coordinated effort aimed at preventing AIDS through development of HIV-1 vaccines. The proposal encompasses the important issues of HIV-1 strain variation and cross-immunogenicity with SIV, the production and composition of conventional and novel HIV immunogens, toxicity tests and induction of HIV-specific humoral and cellular immunity in small animals, and efficacy tests of candidate vaccines in HIV- challenged chimpanzees. Selection of candidate vaccines for efficacy tests in chimps and possible scale up for human use will, thus, be based on a systematic, scientific approach including quantitative estimation of immune response on humoral and cellular levels in guinea pigs and rhesus monkeys. The specific aims of this overall Program Project Grant Proposal are as follows: 1) To compare several HIV-1 strains, selected on the basis of clinical features, biologic properties and serotyping, for toxicity and immunogenicity in guinea pigs and rhesus macaques. 2) Based on results obtained in Aim #1, to develop candidate HIV- 1 vaccine preparations using: a) inactivated whole virus, b) genetically engineered pol mutants, c) recombinant DNA envelope and core subunits expressed in yeast and mammalian cells, and d) effective adjuvants. 3) To test the efficacy of optimum HIV-1 vaccine materials and protocols, chosen on the basis of results obtained above, for protection against HIV-1 challenge in uninfected chimpanzees. This Program Project consists of 5 participating laboratories (Projects I-V) in 4 separate institutions, a) Department of Pathology, University of California, Davis, School of Medicine (UCD)(Project I), b) Tumor Virus Laboratory, Cancer Research Institute, University of California, San Francisco (UCSF)(Project II), c) Chiron Corporation, Emeryville, CA (Project III), d) Liposome Laboratory, Cancer Research Institute (UCSF)(Project IV), and e) Southwest Foundation for Biomedical Research, San Antonio, Texas (Project V). We believe this consortium makes sense by providing the scientific talent, unique resources and administrative competence to carry out the teamwork necessary to accomplish the stated objectives.